BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9556784)

  • 1. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
    Diasio RB
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
    Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
    Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
    Benson AB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
    Schilsky RL; Kindler HL
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
    Hoff PM; Pazdur R
    Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of fluorinated pyrimidines: eniluracil.
    Baker SD
    Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
    Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
    J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [5-fluorouracil and dihydropyrimidine dehydrogenase].
    Kubota T
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of eniluracil: current status.
    Hohneker JA
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil and dihydropyrimidine dehydrogenase.
    Kubota T
    Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
    Diasio RB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.